Celgene

The Union for Affordable Cancer Treatment (UACT) welcomes the news that a Russian court has approved a compulsory license for patents held by Celgene for the cancer drug lenalidomide, marketed in many countries under the trade name Revlimid. Compulsory licenses on patents can promote health and protect the interests of cancer patients when there is excessive pricing and other abuses of a legal monopoly. Since entering the market, Revlimid has generated more than $46 billion in sales for Celgene, including $2.3 billion in the first three months of 2018. In the United States, Celgene still claims the drug is protected by 26 patented inventions andRead More →